CPRX News and Press, Catalyst Pharmaceuticals Inc. From 05/11/22

Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 non-GAAP EPS grew +63.64% Y/Y to $0.18 and the company reaffirmed its FY22 revenue outlook. Total revenues rose +42.66% to $43.03M Y/Y. The company said the increase reflected steady growth for its drug Firdapse, to treat pediatric patients with ...

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Ali Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeff Del Carmen - Chief Commercial Officer Steven Mille...

Catalyst has outperformed during 2022 despite a brutal biotech market. Catalyst minds its knitting and does well by doing so. Catalyst reported strong earnings for Q1 2022. For further details see: Catalyst: Upside Outlier - In Search Of A Catalyst

Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q1 Non-GAAP EPS of $0.18. Revenue of $43.09M (+42.6% Y/Y). Shares +1.6%. Guidance: The Company continues to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% i...

Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE ® Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in In...

CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcos Dorados ( ARCO ): A fast food franchisee serving Latin America. Catalyst Pharmaceuticals ( CPRX ): This biopharmaceutical firm focuses on rare debilitating neuromuscular and neurodegenerative diseases. ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded today at a new 52-week high of $8.41. So far today approximately 301,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) defies analysts with a curren...

Start Time: 08:30 End Time: 09:31 Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2021 Earnings Conference Call March 17, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Alicia Grande - VP, CFO and Treasurer Steven Miller - COO and Chief Scientific Of...

Catalyst Pharmaceuticals (NASDAQ:CPRX) saw its Q4 2021 net income decline ~19% year over year even though revenue increased and beat estimates. Q4 net income stood at ~$9.3M ($0.09 per share, basic and diluted). Revenue increased ~24% year over year to ~$38.1M. Total operating costs and expen...